STOCK TITAN

Incyte (INCY) EVP reports December 2025 insider stock sale filing

Filing Impact
(Very High)
Filing Sentiment
(Very Negative)
Form Type
4

Rhea-AI Filing Summary

Incyte Corporation’s Executive Vice President and Head of Technical Operations reported several sales of company common stock. On December 16, 2025, the officer sold 833 shares at $97.42 per share and 53,175 shares at $97.29 per share. On December 17, 2025, the officer sold 4,323 shares at $97.26 per share. After these transactions, the officer reported beneficial ownership of 27,507 shares, which the filing explains includes shares issuable under previously reported restricted stock units and earned performance stock units that have not yet vested.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Morrissey Michael James

(Last) (First) (Middle)
1801 AUGUSTINE CUT-OFF

(Street)
WILMINGTON DE 19803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Head of Tech. Operations
3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/16/2025 S 833 D $97.42 85,005 D
Common Stock 12/16/2025 S 53,175 D $97.29 31,830 D
Common Stock 12/17/2025 S 4,323 D $97.26 27,507(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes an aggregate of 27,507 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
Remarks:
/s/ Elizabeth Feeney, Attorney-In-Fact 12/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Incyte (INCY) report in this Form 4?

An Executive Vice President and Head of Technical Operations of Incyte reported multiple sales of common stock in mid-December 2025 and updated their beneficial ownership.

How many Incyte (INCY) shares did the executive sell and on which dates?

The officer sold 833 shares and 53,175 shares on December 16, 2025, and 4,323 shares on December 17, 2025, as disclosed in the Form 4 table.

At what prices were the Incyte (INCY) shares sold in this filing?

The reported sales were at per-share prices of $97.42, $97.29, and $97.26 for the different transactions in the company’s common stock.

How many Incyte (INCY) shares does the executive report beneficially owning after these trades?

Following the reported transactions, the executive reports beneficial ownership of 27,507 shares of Incyte common stock.

What does the note about restricted stock units and performance stock units mean for Incyte (INCY)?

The filing explains that the 27,507 shares include common stock issuable from previously reported restricted stock units and earned performance stock units that have not yet vested.

Is the Incyte (INCY) insider transaction reported by a single person or a group?

The Form 4 indicates it is filed by one reporting person, not by more than one reporting person.
Incyte Corp

NASDAQ:INCY

INCY Rankings

INCY Latest News

INCY Latest SEC Filings

INCY Stock Data

19.52B
194.97M
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON